Scientists make breakthroughs in research on hepatitis C virus vaccine November 14, 2016 Source: Drug Information Network The therapeutic drug peginterferon combined with ribavirin can only cure about 50% of patients, especially for type 1 HCV infection; the new-generation drug DAAs will increase the cure rate to over 90%. But new drugs are extremely expensive and have the potential to develop resistance. Therefore, the development of safe and effective preventive HCV vaccine is of great significance to alleviate this global public health burden and completely solve the hepatitis C problem. However, due to factors such as high frequency mutations in the HCV genome, glycosylation of envelope proteins, viral particles encapsulated by lipid molecules, and non-neutralizing antibody interference, how to induce the neutralization of all seven viral subtypes Antibodies have always been the biggest difficulty in the development of HCV vaccines. There are currently no preventive vaccines for HCV. Probiotics are a class of active microorganisms that are beneficial to the host by colonizing the human body and changing the composition of the flora in a certain part of the host. By regulating the immune function of the host mucosa and system or by regulating the balance of intestinal flora, promoting nutrient absorption and maintaining intestinal health, resulting in the production of single microorganisms or mixed microorganisms with well-defined composition that are beneficial to health. Probiotics,Probiotic Efficacy,Probiotic vitamins,Probiotic Health Supplements YT(Xi'an) Biochem Co., Ltd. , https://www.ytwholefood.com
Recently, the Huang Zhong Group of the Shanghai Pasteur Institute of the Chinese Academy of Sciences and the Zhong Jin Research Group have made breakthroughs in the research of hepatitis C virus (HCV) vaccine. The research results "the change in the type of glycosylation enhances the immunogenicity of the hepatitis C virus subunit vaccine and the inducibility of protective neutralizing antibodies" has been published online in the international academic journal Journal of Virology.
　Â
Li Dapeng, a Ph.D. student at Shanghai Pasteur Institute, under the guidance of researchers Huang Zhong and Zhong Jin, used the HCV envelope protein E2 as a vaccine target to prepare soluble E2 protein (sE2) using Drosophila S2 recombinant expression system, and systematically evaluated it. The immunogenicity of the sE2 vaccine, the ability to induce broad-spectrum neutralizing antibodies and its protective effect on mouse infection models. The results showed that the sE2 vaccine-immunized mice were able to induce a broad-spectrum neutralizing antibody against all seven subtypes of HCV. More importantly, the Shanghai Pasteur team collaborated with Princeton University professor Alexander Ploss to determine the sE2 vaccine. It can effectively prevent HCV infection in a humanized mouse model and has a good immune protection effect.
Â
Further mechanistic studies have found that the sE2 protein expressed by insect cells has a simpler glycosylation type compared to antigens derived from mammalian systems, and this simple glycosylation modification is effective for sE2 to induce broad-spectrum neutralizing antibodies. Critical. The sE2 subunit vaccine developed by the project is superior to the HCV candidate vaccine currently in clinical trials in inducing broad-spectrum neutralizing antibodies , and the vaccine has simple composition and high yield, so it has a good industrialization prospect.